HUNTINGDON, Cambridgeshire, United Kingdom – 1 March 2021 – The global clinical trial services provider The SMO Group has announced today that the company will begin operating under a new name and will be known henceforth as Oximio, effective immediately. The 18 months extensive rebranding project is a response to the accelerated company growth and a renewal of the company vision.
“By announcing Oximio, we are opening the next chapter in the company’s history. In the past 16 years we have grown to become a truly global company, constantly focusing on further geographical expansion and strengthening our service portfolio. In the past years we put a huge effort into developing a quality led organization, which has resulted in higher patient satisfaction and a wider service coverage.
I believe it was appropriate to rebrand our company to better reflect the fresh and professional mindset of our people and to emphasize the knowledge, expertise and added value we bring to the clinical research market.” – CEO, Krisztina Varga stated. “The new brand will help us seize the opportunity to reinforce our reputation of being a well-established clinical trials services provider, building on our history and our strong company culture. We aim to provide a full brand experience to our clients to help them be more successful in their core business.
We will be working extremely hard to achieve our vision: We are dedicated to expediting research to find effective treatments and cures for all living beings.”
The company’s ownership, staff, and legal entity names remain unchanged. Both names – SMO GROUP® and OXIMIO®, as our registered trademarks will be used within a transition period and thereafter on per case basis.
For more information about the brand change please visit our new website: oximio.com.
About Oximio
Oximio is a clinical trial services provider contributing to research to find effective treatment and cures for all living beings, globally. Oximio works hard to convert the ever-changing face of investigational medical products into new medicines, bringing over 16 years of service excellence to the clinical trial industry. The company provides a direct connection to several patient communities of over 500 million people by being present in the United Kingdom, Eastern Europe, Western Asia, and South Africa. Oximio’s large and loyal client base ranges from start-ups to major international organizations, pharmaceutical and R&D companies. Oximio is in the front line of servicing clinical trials with its’own warehouses and, through licensed partner sites, offers an end-to-end cold-chain control system in all premises. By combining its’ ‘best-in-class’ depot network with a highly experienced and qualified workforce, Oximio is thoroughly conversant with both global and local procedures for clinical trials, ensuring the highest standards of operation. Oximio has the following capabilities: supply planning and consulting, comparator sourcing, patient centricity, advanced therapy solutions, import & export regulations, relabelling, warehousing, distribution and courier services, return & destruction.